Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Oporia Is “Not Approvable” For Osteoporosis Prevention

This article was originally published in The Pink Sheet Daily

Executive Summary

The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.
Advertisement

Related Content

Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis
Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
Wyeth Files Simultaneous NDAs For Women’s Health Treatments
Pfizer’s COX-2 Parecoxib Is “Not Approvable”
Oporia Osteoporosis NDA Review Extended To September
Oporia Osteoporosis NDA Review Extended To September
Pfizer/Ligand's Lasofoxifene Is First "Next-Generation" SERM Filed At FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS062874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel